Mastering Clinical Challenges and Emerging Therapies in IBD

Memo

Mastering Clinical Challenges and Emerging Therapies in IBD is taking place on July 21, 2018 in Chicago and can't be missed. After the conference, participants will be able to: -Assess the mechanism of action and therapeutic potential of evolving treatments in IBD-Evaluate strategies for sequencing therapeutics in the era of biologics, immunotherapies, and biosimilars -Identify a personalized therapeutic approach to optimally manage complex cases of Crohn's disease-Interpret pivotal clinical trial data and novel management strategies for integration into clinical practice-Describe therapeutic strategies designed to prevent infections and extraintestinal manifestations in IBD-Define the role of treat-to-target in IBD regimens designed to maximize the opportunity to achieve remission and avoid relapse-Identify strategies to de-escalate therapy once remission is achieved in IBD-Assess the emerging role of biosimilars in IBD therapy and their integration into current standards of care Our conference chair is David T. Rubin, MD, FACG and will feature 4 interactive sessions. To view the full scientific agenda visit clinicalchallengesinibd.com.   Tickets:  https://go.evvnt.com/241610-2?pid=5569  Time: 08:00 to 17:00. Venue details: The Gwen, 521 North Rush Street, Chicago, 60611, United States. Prices:Physician, Pharmacist, PhD: USD 249.0,Nurse, PA, NP, Student, Fellow, Trainee: USD 129.0,Industry: USD 325.0. Speakers: Aline Charabaty, MD, Russell D. Cohen, MD, FACG, Jean-Frederic Colombel, MD, Raymond K. Cross, Jr., MD, MS, Sushila Dalal, MD, Stephen B. Hanauer, MD, FACG, David P. Hudesman, MD, David T. Rubin, MD, FACG, Conference Chair